Synthetic peptide amide dimers

Details Synthetic peptide amide dimers Synthetic peptide amide dimers

2007-11-12

2010-11-30

Bradley, Christina (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07842662

ABSTRACT:
The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

REFERENCES:
patent: 5965701 (1999-10-01), Junien et al.
patent: 6191103 (2001-02-01), Shohet et al.
patent: 6780846 (2004-08-01), O'Mahony et al.
patent: 6984719 (2006-01-01), Chemtob et al.
patent: 2005/0113294 (2005-05-01), Dolle
patent: 2006/0229252 (2006-10-01), Falla et al.
patent: 43 10643 (1993-04-01), None
patent: 0 249 169 (1987-06-01), None
patent: 0 334 244 (1989-03-01), None
patent: 0 342 962 (1989-05-01), None
patent: 0 361 977 (1989-09-01), None
patent: 0 505 680 (1992-01-01), None
patent: 0 517 589 (1996-12-01), None
patent: 0 503 301 (1997-11-01), None
patent: WO 88/08429 (1988-11-01), None
patent: WO 94/21242 (1994-09-01), None
patent: WO 95/00546 (1995-01-01), None
patent: WO 95/22557 (1995-08-01), None
patent: WO 96/02267 (1996-01-01), None
patent: 96/40206 (1996-12-01), None
patent: WO 97/07130 (1997-02-01), None
patent: WO 97/09995 (1997-03-01), None
patent: WO 98/08492 (1998-03-01), None
patent: WO 98/08868 (1998-03-01), None
patent: WO 99/21877 (1999-05-01), None
patent: WO 99/32510 (1999-07-01), None
patent: WO 03/011896 (2003-01-01), None
patent: WO 2006/058539 (2006-06-01), None
patent: WO 2006/058539 (2006-06-01), None
patent: 2007/139826 (2007-12-01), None
patent: 2007/139921 (2007-12-01), None
patent: 2008/057608 (2008-05-01), None
patent: 2008/077194 (2008-07-01), None
Portoghese “From Models to Molecules: Opioid Receptor Dimers, Bivalent Ligands, and Selective Opioid Receptor Probes,” J. Med. Chem., 2001, 44, 2259-2269.
Mollica et al. “Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers,” Bioorganic & Medicinal Chemistry Letters 15 (2005) 2471-2475.
Aggarwal et al. “Synthesis and Screening of a Random Dimeric Peptide Library Using the One-Bead-One-Dimer Combinatorial Approach,” Bioconjugate Chem. 2006, 17, 335-340.
Testa “Prodrug research: futile or fertile?” Biochemical Pharmacology, 2004, 68, 2097-2106.
Byrn et al. Solid State Chemistry of Drugs, 2 Ed. 1999 “Hydrates and Solvates” pp. 233-247.
Binder W et al. “Analgesic and anti-inflammatory effects of two novel kappa-opioid peptides”, Anesthesiology 94(6): 1034-1044, Jun. 2001.
Wisniewski K et al. “Long acting, selective, peripheral kappa agonists”, Peptides, Proceedings of the European Peptide Symposium, 775-776, meeting date 2000, 2001.
Dooley C T et al. “Selective ligands for the mu, delta and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library”, Journal of Biological Chemistry 273(30): 18848-18856, Jul. 24, 1998.
Costa T et al. “Receptor binding and biological activity of bivalent enkephalins”, Biochemical Pharmacology 34(1): 25-30, Jan. 1, 1985.
Shimohigashi Y et al. “Dimeric tetrapeptide enkephalins display extraordinary selectivity for the delta opiate receptor”, Nature 297(5864): 333-335, May 27, 1982.
Vanderah T W et al. “FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): a peripheral efficacious kappa opioid agonist with unprecedented selectivity”, the Journal of Pharmacology and Experimental Therapeutics 310(1): 326-333, Jul. 2004.
Donaldson V H et al. “Effect of some analogues of bradykinin upon vascular permeability”, Proceedings of the Society for Experimental Biology and Medicine 125(1): 145-148, May 1967.
Vippagunta et al. “Crystalline solids”, Adv. Drug Delivery Rev. 48 (2001) 3-26.
Bentley, G.A. et al., Evidence for an action of morphine and the enkephalins on sensory nerve endings in the mouse peritoneum, Br. J. Pharmac., 73:325-332 (1981).
Diop, Laurent et al., Peripheral k-opioid receptors mediate the antinociceptive effect of fetodozine on the duodenal pain reflex in rat, European Journal of Pharmacology 271, pp. 65-71 (1994).
Iyer, S. et al., Characterization and Biological Significance of Immunosuppressive Peptide D2702.75-84 (E→V) Binding Protein, J. Biol. Chem., vol. 273, No. 5, pp. 2692-2697 (1998).
Junien and Riviere, Review article: the hypersensitive gut—peripheral kappa agonists as a new pharmacological approach, Alimentary Pharmacology and Therapeutics, 9:117-126 (1995).
Lamb, J.R. et al., Influence of antigen structure on the activation and induction of unresponsiveness in cloned human T lymphocytes, Immunology, 57, pp. 331-335 (1986).
Ostergaard, S. et al., Novel avidin and streptavidin binding sequences found in synthetic peptide libraries, FEBS Letters, 362, pp. 306-308 (1995).
Riviere, Pierre J.M. et al., Fedotozine Reverses Ileus Induced by Surgery or Peritonitis: Action at PeripheralK-Opioid Receptors, Gastroenterology 104:724-731 (1993).
Samson, Isabelle et al., Screening a Random Pentapeptide Library, Composed of 14 D-Amino Acids, against the COOH-terminal Sequence of Fructose-1,6-bisphosphate Aldolase fromTrypanosoma brucei,The Journal of Biological Chemistry, vol. 272, No. 17, Issue Apr. 25, pp. 11378-11383 (1997).
Schröder, E., Synthese des all-D-Val5-Angiotensin II-Asp1-β-amids, J. Liebigs Ann Chem, pp. 241- (1966).
Seo, Jeong Kon et al., A Peptide with Unique Receptor Specificity, Jimmunol, pp. 1895-1901 (1997).
Vanderah, T.W. et al., Mediation of Swim-Stress Antinociception by the Opioid Delta2Receptor in the Mouse1, J. Pharm. Exper. Therapeutics, vol. 262:1 (1992).
Vogler, von K. et al., Synthese von All-D-Val5-Angiotensin II-Asp1-β-Amid1), Hely Chim Acta, 48:6:152, pp. 1407-1414 (1965).
Vonvoigtlander, P.F. et al., U-50,488: A Selective and Structurally Novel Non-Mu (Kappa) Opioid Agonist, J. Pharm. Exper. Therapeutics, 224:7-12 (1983).
Wang, X. et al., Applications of topologically segregated bilayer beads in ‘one-bead one-compound’ combinatorial libraries, J. Peptide Res. 65, pp. 130-138 (2005).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, J. Peptide Sci., 6 supp:S189 (2000) (Abstract).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, Posters:1 Bioactive, P358 (Poster).
Wisniewski, K. et al., Long Acting, Selective, Peripheral Kappa Agonists, Peptides 2000:Proc. of 36thEur Peptide Symp. (J. Martinez & J.A. Fehrentz, eds.) Editions EDK, pp. 775-776 (2001) (Mini-publication).

Affiliated with

Also associated with

Rating

Synthetic peptide amide dimers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic peptide amide dimers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptide amide dimers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4188456